Treatment of Tourette's syndrome with mecamylamine

Lancet

Volumn 352, Issue 9129, 1998, Pages 705-706

  Sanberg, Paul R ^a,b   Douglas Shytle, R ^a   Silver, Archie A ^a  

^a Departments of Surgery   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MECAMYLAMINE; NICOTINIC RECEPTOR; SERTRALINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; GILLES DE LA TOURETTE SYNDROME; HUMAN; MALE; MOOD; PRIORITY JOURNAL; SCHOOL CHILD; TIC;

EID: 0032578304     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)60822-7     Document Type: Article

References (5)

1. Silver AA, Sanberg PR. Transdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome. Lancet 1993; 342: 182.
2. McConville BJ, Sanberg PR, Fogelson M H , et al. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder. B loi Psychiatry 1992; 31: 832-40.
3. Dursun SM, Reveley MA, Bird R, Stirton F. Long lasting improvement of Tourette's syndrome with transdermal nicotine. Lancet 1994; 344: 1577.
4. NIMH. CGI (Clinical Global Impression) Scale. Psychopharmacol tf 1985;21: 839-43.
5. Collins AC, Marks MJ. Are nicotinic receptors activated or inhibited following chronic nicotine treatment? Drug Development Research 1996; 38: 231-42.